about
Challenges in implementing and maintaining osteoporosis therapy.Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.New strategies for osteoporosis patients previously managed with strontium ranelate.International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonatesRisk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).Association between gastrointestinal events and compliance with osteoporosis therapy.Treatment responses with once-weekly teriparatide therapy for osteoporosis.Safety and efficacy of generic drugs with respect to brand formulation.Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.Surgeons save bones: an algorithm for orthopedic surgeons managing secondary fracture prevention.Bone markers and osteoporosis therapy.Goal-directed treatment of osteoporosis in Europe.Swedish osteoporosis care.Treatment of osteoporosis after alendronate or risedronate.Population Pharmacokinetic and Exposure-Response Analysis of Weekly Teriparatide in Osteoporosis Patients.Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis.Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004-2015.Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.Bone loss at the distal femur and proximal tibia in persons with spinal cord injury: imaging approaches, risk of fracture, and potential treatment options.Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study.The clinical utility of bone turnover markers in the evaluation of bone disease in patients with haemophilia A and B.Goal-directed treatment of osteoporosis.[Osteoporosis: therapy in interface management].Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs.Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.Treatment of postmenopausal osteoporosis: a literature-based algorithm for use in the public health care system.Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.Osteoporosis pharmacogenomics: recent insights and future perspectives.The Association between Daytime Napping Characteristics and Bone Mineral Density in Elderly Thai Women without Osteoporosis.Can Change in FRAX Score Be Used to “Treat to Target”? A Population-Based Cohort Study
P2860
Q34073740-7E0CBFBE-8BEE-4489-8C24-48ADF0A3A49AQ34459547-0A58DAB7-C8BE-46A3-8278-6702AF1A6476Q34536861-8DF6F30E-5761-4188-9C61-AC20B46DEA7EQ34550435-A1AC00E7-9309-455A-82B3-5D729124144DQ36250826-65DDFE4A-BFBC-4F70-8F1A-77914C3F754DQ36930096-9F7488BE-2B26-4708-BE1D-B4D0FE9DBD10Q37051660-5231E1E0-1A4B-470C-825F-7A360751C561Q37298025-A6351A2A-632C-4917-B087-9F2305D8390AQ37369626-EB259C86-93F4-4B36-AAAB-FF6076BDF0E1Q37401919-95B4C0BD-7280-4D08-A327-B6C8B9AFAB68Q38107423-37C2AF11-5FA1-4A1F-BA75-335EE8BA539CQ38244170-C0F63615-0D16-4A75-89E9-1E9D636CD40FQ38246948-5223888B-0387-4254-ACF9-BBDDAAA5EE1EQ38563886-D3522820-40D9-4661-875D-73A826B5E4C3Q38599682-6B5E76BD-65F5-45D2-80E2-5CEE2DD5CA9BQ38725697-75CA1E9F-9A0A-4756-AF5E-1F58749A1200Q38739527-AC145A2B-D517-4F18-8B13-D3080B185648Q38790108-DE2DE1AD-464B-498C-A6AE-2485E1F239B7Q38793382-9943DA2D-74CD-4CBC-B043-1B87B2CD184FQ39030288-73834297-798B-4C3C-852A-DD9408D8C38CQ40160557-CD255F51-AE07-48C0-A91A-169337D6378FQ40736476-4CA29799-13CC-4E2B-A832-9F2446D7F906Q42263129-89F05583-B794-45A8-8F42-12AE05545531Q44874767-DDB9706C-32CF-47FE-84A5-672CA7EAD819Q45801957-3624FD58-330B-4BD7-B31F-3198522CB175Q47110800-1774F2A7-9155-476B-9477-4F741E61C291Q47552430-2364BC0D-A0DF-4956-80D7-6DE45B652B68Q47981699-D2926A90-2273-4FE8-B627-C63221845698Q50052201-D776796F-383F-4331-9FD8-EC6B9FF88502Q51462132-8F59B3F2-BE8A-4BCE-8FF9-8A4D45C9433AQ55656113-E9F4DC9A-AAF6-4086-993F-876278DB77DDQ57711187-AD4A0E8A-7853-4025-BAC3-7F167336ED73
P2860
description
im Juli 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 27 July 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2012
@uk
name
Treatment failure in osteoporosis
@en
Treatment failure in osteoporosis
@nl
type
label
Treatment failure in osteoporosis
@en
Treatment failure in osteoporosis
@nl
prefLabel
Treatment failure in osteoporosis
@en
Treatment failure in osteoporosis
@nl
P2093
P2860
P50
P1476
Treatment failure in osteoporosis
@en
P2093
D Agnusdei
E F Eriksen
IOF CSA Inadequate Responders Working Group
J D Adachi
J E Compston
J Gonzalez-Macias
J P Bilezikian
S R Cummings
P2860
P2888
P304
P356
10.1007/S00198-012-2093-8
P407
P577
2012-07-27T00:00:00Z